Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase IIIa data suggest that the benefit of Novo's ultra-long acting insulin Degludec over Sanofi's Lantus is fewer nocturnal hypoglycemic events.
You may also be interested in...
Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety
In briefing documents for the Nov. 8 panel review, FDA suggests the clinical trial data do not support Novo Nordisk’s assertion of a hypoglycemia advantage with its new long-acting insulin. Agency also raises concerns about a meta-analysis suggesting an increased cardiovascular risk.
Investors Optimistic On FDA Panel For Novo’s Insulin Degludec
Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.